Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Nemolizumab Dose-finding Trial in Chronic Pruritus of Unknown Origin
jRCT2031240523Phase 2Active, not recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nemolizumab in chronic idiopathic pruritus (3 arms), sponsored by Maruho Co., Ltd. Primary endpoint: Percent change from baseline in weekly average of Peak Pruritus Numeric Rating Scale at Week 16. Started Feb 2025; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on jRCT2031240523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240523.